Multiple myeloma staging

Multiple myeloma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Multiple Myeloma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
Echocardiograph and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Future or Investigational Therapies
Case Studies
Case #1
Multiple myeloma staging On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Multiple myeloma staging All Images X-rays Echo and Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Multiple myeloma staging
CDC on Multiple myeloma staging
Multiple myeloma staging in the news
Blogs on Multiple myeloma staging
Directions to Hospitals Treating Multiple myeloma
Risk calculators and risk factors for Multiple myeloma staging

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

International Staging System for multiple myeloma, based on β2-microglobulin (β2M) levels and serum albumin levels, was published by International Myeloma Working Group in 2003 and is the most widely used staging system. It is used for both guiding treatment as well as predicting prognosis.

Staging

International Staging System

According to the International Staging System (ISS), there are three stages of multiple myeloma based on both β2-microglobulin and Albumin levels.:

Stage	Features	Prognosis
Stage 1	β2-microglobulin < 3.5 mg/L and Albumin >= 3.5 g/dL	Median survival of 62 months
Stage 2	β2-microglobulin <3.5 and Albumin <3.5 or β2-microglobulin 3.5-5.5	Median survival 45 months
Stage 3	β2-microglobulin >5.5	Median survival 29 months

Durie-Salmon staging system

According to the Durie-Salmon Staging System, there are three stages of multiple myeloma based on the hemoglobin level, calcium level, skeletal survey, serum parapprotein level, and urinary light chain excretion. First published in 1975, the Durie-Salmon staging system (Durie BG, Salmon SE) is a clinical staging system for multiple myeloma that correlates measured myeloma cell mass with the presenting clinical features, response to treatment, and survival.</ref> Durie-Salmon Staging System is still in use, but has largely been superseded by the simpler ISS.

Stage	Hemoglobin level	Calcium level	Skeletal survey	Serum paraprotein level	Urinary light chain excretion
Stage 1	> 10g/dL	8.5-10.2 mg/dL	Normal or single plasmacytoma or osteoporosis	< 5 g/dL if IgG or < 3 g/dL if IgA	< 4 g/24h
Stage 2	8.5-10g/dL	10.2-12 mg/dL	fulfilling the criteria of neither 1 nor 3	5-7 g/dL if IgG or 3-5 g/dL if IgA	4-12 g/24h
Stage 3	< 8.5g/dL	> 12mg/dL	3 or more lytic bone lesions	>7g/dL if IgG or > 5 g/dL if IgA	> 12g/24h

Stages 1, 2 and 3 of the Durie-Salmon staging system can be divided into A or B depending on serum creatinine:

• A: serum creatinine < 2mg/dL (< 177 umol/L)
• B: serum creatinine > 2mg/dL (> 177 umol/L)

References

Template:WikiDoc Sources